GPRC5D CAR-T: a new path beyond BCMA

In this issue of Blood, Bal et al 1 report the results of a first-in-human, phase 1 dose-escalation and expansion study evaluating arlocabtagene autoleucel (arlo-cel), a G protein-coupled receptor family C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy, in patients with heavily pretreated relapsed/refractory multiple myeloma (R/RMM).The study enrolled 84 patients who had received a median of 5 prior lines of therapy, including immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies, with nearly half previously exposed to B-cell maturation antigen (BCMA)-targeted therapies.